The Role of Oncotype DX
Oncotype DX® is intended for use in conjunction with
other conventional methods of breast cancer analysis. Together with staging,
grading and other tumor marker analyses, Oncotype DX can provide greater
insight into the likelihood of systemic disease recurrence. The quantitative
assessment of the likelihood of distant recurrence provided by Oncotype DX
is important in weighing the benefits vs. the risks of adjuvant chemotherapy in
order to determine the most appropriate treatment strategy – increasing
confidence that the treatment plan is tailored to the individual patient.
Based on the population for which Oncotype DX was developed and
validated, the assay is intended for newly diagnosed patients whose breast
cancer is stage I or II, node-negative and estrogen receptor-positive. Oncotype DX now offers
clinical experience information for newly diagnosed women who are post-menopausal and have node positive, estrogen receptor positive breast cancer and who will be treated with tamoxifen. Clinical studies in
other populations are currently under way.
|
 |
|
